https://www.selleckchem.com/pr....oducts/Cyclopamine.h
Whereas prospective follow-up is ongoing, among those who had already completed the long-term follow-up visits (n=51), reductions in pain intensity, disability, and pain interference were sustained in a majority of participants through 14months after the start of treatment. Given the minimally invasive, nondestructive nature of percutaneous PNS and the significant benefits experienced by participants who were recalcitrant to nonsurgical treatments, percutaneous PNS may provide a promising first-line neurostimulation treatment option
Curtir
Comentario
Compartilhar
